Topics

  • HOME
  • TOPICS
  • Topics
Correspondence
Correspondence to editorial on: “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”
Satya Priya Sharma, Ki Tae Suk
Clin Mol Hepatol. 2025;31(1):e74-e77.   Published online October 15, 2024
View: 783   Download: 42
Letter to the Editor
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs
Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau
Clin Mol Hepatol. 2025;31(1):e19-e20.   Published online October 17, 2024
View: 515   Download: 29
Correspondence
Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer
Clin Mol Hepatol. 2025;31(1):e44-e47.   Published online October 21, 2024
View: 704   Download: 38  Crossref: 1
Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol. 2025;31(1):e98-e100.   Published online October 21, 2024
View: 554   Download: 42
Letter to the Editor
2077
Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China
Lei Cai, Chao Li, Li-Yang Sun, Yong-Kang Diao, Ming-Da Wang, Tian Yang
Clin Mol Hepatol. 2025;31(1):e39-e43.   Published online October 23, 2024
View: 552   Download: 50
Correspondence
Correspondence to editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multinational population-based cohort study from South Korea, Japan, and the UK”
Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Hayeon Lee, Yeonjung Ha, Dong Keon Yon
Clin Mol Hepatol. 2025;31(1):e87-e89.   Published online October 29, 2024
View: 486   Download: 13  Crossref: 1
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
Hee Yeon Kim, Miyoung Choi, Dae Won Jun
Clin Mol Hepatol. 2025;31(1):e105-e107.   Published online November 4, 2024
View: 401   Download: 19
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su
Clin Mol Hepatol. 2025;31(1):e101-e102.   Published online November 6, 2024
View: 401   Download: 12
Letter to the Editor
Insights on risk score development: Considerations for early-stage hepatocellular carcinoma models
Zhanna Zhang, Gongqiang Wu
Clin Mol Hepatol. 2025;31(1):e8-e9.   Published online November 6, 2024
View: 497   Download: 25  Crossref: 1
Reply to Correspondence
Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
Mirko Zoncapè, Emmanuel A. Tsochatzis
Clin Mol Hepatol. 2025;31(1):e117-e118.   Published online November 11, 2024
View: 426   Download: 15
Correspondence
Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”
Yu-Hang Ye, Shao-Lai Zhou
Clin Mol Hepatol. 2025;31(1):e90-e92.   Published online November 11, 2024
View: 461   Download: 15
Correspondence to letter to the editor 1 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su
Clin Mol Hepatol. 2025;31(1):e96-e97.   Published online November 11, 2024
View: 402   Download: 10
Letter to the Editor
Grading severity of microvascular invasion in hepatocellular carcinoma: More details, more significance
Xiu-Ping Zhang, Fei-Fan Wu, Tian-Chen Zhang, Zhen-Qi Li, Ming-Gen Hu, Rong Liu
Clin Mol Hepatol. 2025;31(1):e10-e12.   Published online November 26, 2024
View: 780   Download: 56
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus
Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng
Clin Mol Hepatol. 2025;31(1):e23-e24.   Published online November 26, 2024
View: 411   Download: 17
The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread
Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang
Clin Mol Hepatol. 2025;31(1):e25-e26.   Published online December 10, 2024
View: 490   Download: 37
Erratum
1981
Erratum to ‘Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction’ [Clin Mol Hepatol 2024;30:539-560]
Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim
Clin Mol Hepatol. 2024;30(4):1060-1065.   Published online July 24, 2024
View: 1147   Download: 29  Web of Science: 1  Crossref: 1
Snapshot
1901
Examining the therapeutic landscape of beta-blockers in portal hypertension
Anna Brujats, Càndid Villanueva
Clin Mol Hepatol. 2024;30(4):1055-1059.   Published online March 6, 2024
View: 6071   Download: 68
Reply to Correspondence
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
Cho-Rong Lee, Sung-Gyoo Park
Clin Mol Hepatol. 2024;30(4):1053-1054.   Published online July 17, 2024
View: 1434   Download: 44  Web of Science: 1  Crossref: 1
Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
Seren M. Gedallovich, Paul Y. Kwo
Clin Mol Hepatol. 2024;30(4):1050-1052.   Published online July 12, 2024
View: 1146   Download: 34
Reply to correspondence on “Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis”
Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang
Clin Mol Hepatol. 2024;30(4):1042-1043.   Published online August 27, 2024
View: 967   Download: 30  Web of Science: 1  Crossref: 2
Reply to correspondence on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”
Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
Clin Mol Hepatol. 2024;30(4):1037-1038.   Published online May 2, 2024
View: 1406   Download: 54
Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
Eileen Laurel Yoon, Dae Won Jun
Clin Mol Hepatol. 2024;30(4):1033-1034.   Published online May 20, 2024
View: 1141   Download: 26
Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
Pin-Nan Cheng, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(4):1031-1032.   Published online April 11, 2024
View: 1473   Download: 56

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1680
TOTAL : 2434558
Close layer